+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Towards improved pharmacotherapy in pulmonary arterial hypertension. Can diet play a role?

Towards improved pharmacotherapy in pulmonary arterial hypertension. Can diet play a role?

Clinical Nutrition Espen 30: 159-169

Pulmonary arterial hypertension (PAH) is a rare, progressive disease of the pulmonary vasculature. Recent advances in pharmacotherapy improved life expectancy of PAH patients and, thus, signified the role of general measures, including diet, in the management of the disease. In the present narrative review we will briefly summarize information about current and novel PAH therapies and analyze preclinical evidence on the influence of certain nutrients on the pathogenesis of PAH. Although the evidence on the role of dietary deficiencies in the development and progression of PAH in humans is limited, preclinical studies demonstrate that dietary components such as quercetin, genistein, n-3 PUFAs, vitamin D, coenzyme Q10 and resveratrol may influence various aspects of PAH pathobiology. Further research on the role of diet in PAH is needed. Taking into account pleiotropic and subtle effects of dietary constituents as well as the rare and severe nature of PAH, clinical studies on the disease-specific nutritional patterns rather than on single dietary components may help to reveal if diet can be an important tool to improve the efficacy of pharmacotherapy in PAH.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 066618812

Download citation: RISBibTeXText

PMID: 30904217

DOI: 10.1016/j.clnesp.2018.12.087

Related references

Living With Severe Pulmonary Arterial Hypertension Without an Infusion Pump? Selexipag has a Role to Play. Archivos de Bronconeumologia 55(2): 102-103, 2019

Pharmacotherapy of chronic pulmonary arterial hypertension: value and limitations. Part I: Primary pulmonary hypertension. Angiology 45(8): 667-676, 1994

Pharmacotherapy of chronic pulmonary arterial hypertension: value and limitations. Part II: Secondary pulmonary hypertension. Angiology 45(9): 755-761, 1994

Lysyl oxidases play a causal role in vascular remodeling in clinical and experimental pulmonary arterial hypertension. Arteriosclerosis Thrombosis and Vascular Biology 34(7): 1446-1458, 2014

Pharmacotherapy for pulmonary arterial hypertension. Heart Failure Clinics 8(3): 385-402, 2012

Pulmonary arterial capacitance in children with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease: relation to pulmonary vascular resistance, exercise capacity, and survival. American Heart Journal 162(3): 562-568, 2011

Novel approaches to the pharmacotherapy of pulmonary arterial hypertension. Drug Discovery Today 14(5-6): 284-290, 2009

The current pharmacotherapy of pulmonary arterial hypertension. Polski Merkuriusz Lekarski 38(223): 34-38, 2015

Pulmonary arterial hypertension: a review in pharmacotherapy. Cardiology in Review 23(1): 33-51, 2015

New pharmacotherapy options for pulmonary arterial hypertension. Expert Opinion on PharmacoTherapy 16(14): 2113-2131, 2015

Update on pulmonary arterial hypertension pharmacotherapy. Postgraduate Medicine 128(5): 460-473, 2016

Practical considerations for the pharmacotherapy of pulmonary arterial hypertension. PharmacoTherapy 32(9): 838-855, 2012

Progress in pharmacotherapy of pulmonary arterial hypertension in children. Zhongguo Dang Dai Er Ke Za Zhi 14(3): 236-240, 2012

Clinical pharmacotherapy and drug development for pulmonary arterial hypertension. Recent Patents on Cardiovascular Drug Discovery 6(3): 180-188, 2011

Pharmacotherapy for idiopathic pulmonary arterial hypertension during the past 25 years. PharmacoTherapy 26(1): 68-94, 2006